OncoZenge AB (publ) (STO:ONCOZ)

Sweden flag Sweden · Delayed Price · Currency is SEK
5.74
-0.61 (-9.61%)
Mar 9, 2026, 3:19 PM CET
-4.65%
Market Cap 80.64M
Revenue (ttm) 2.78M
Net Income (ttm) -15.94M
Shares Out 14.05M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,810
Average Volume 11,460
Open 6.35
Previous Close 6.35
Day's Range 5.72 - 6.35
52-Week Range 3.72 - 10.28
Beta 1.34
RSI 59.12
Earnings Date Feb 18, 2026

About OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 1
Stock Exchange Nasdaq Stockholm
Ticker Symbol ONCOZ
Full Company Profile

Financial Performance

In 2025, OncoZenge AB's revenue was 2.78 million, an increase of 278300.00% compared to the previous year's 1,000. Losses were -15.94 million, 83.5% more than in 2024.

Financial Statements

News

There is no news available yet.